Chinese agriculture regulators approved Zhejiang Hisun Pharmaceutical's (SHA:600267) methylprednisolone drug registration for dogs, according to a Friday disclosure to the Shanghai bourse.
The drug is indicated for inflammation and allergies in dogs, including allergic or nonspecific dermatitis, or immune-mediated conditions, the filing said.
Shares rose 2% during afternoon trading on Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments